Patient explainer · Learn
Autologous vs. donor-derived stem cells.
Your own cells, harvested and used in the same procedure, or cells from a different person, often manufactured at scale. The FDA treats these very differently and so do we.
Direct answer
Autologous cells are your own, collected and used in the same procedure. Donor-derived (allogeneic) cells come from a different person, often from umbilical cord blood, placental tissue, or amniotic membrane, and are usually manufactured in large batches and shipped to clinics.
01 · Definitions
Definitions.
Autologous material comes from your own body: bone marrow from the back of your hip bone (the iliac crest), or blood from a vein. It is used only in your own procedure, and no other person's tissue is involved.
Donor-derived cells. From a different person. Almost always processed and manufactured at scale before being shipped to clinics.
Specifically, cells from birth-associated tissues: umbilical cord blood, umbilical cord tissue (Wharton's jelly), placental tissue, amniotic membrane, amniotic fluid. These are collected after delivery, processed by manufacturers, and sold to clinics for injection. They are donor-derived and almost always require FDA approval to market for any specific indication.
A regulatory term for cells that have been only lightly processed (spun in a centrifuge, filtered, or separated) without changing their relevant biological characteristics. Autologous bone marrow concentrate (BMAC) prepared in a same-day procedure typically qualifies.
Cells grown in culture in a lab to increase their number, often over days to weeks. Once cells are expanded, they typically lose their "minimally manipulated" status and cross into FDA drug-product territory: requiring approval before they can be marketed.
02 · The regulatory line
How the FDA treats each.
The framework is the Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) framework, codified at 21 CFR 1271.1 It draws a hard line between two categories:
Cells that meet specific criteria: minimally manipulated, used homologously, not combined with another article, with no systemic effect or dependence on metabolic activity. These can be marketed without FDA pre-market approval. Same-day, autologous, minimally-manipulated bone marrow concentrate typically falls into this category.
Cells that don't meet those criteria. Expanded cells, non-homologous use, combination products, products that depend on metabolic activity for their primary effect. These are regulated as drugs or biologics, and require an Investigational New Drug (IND) application or full FDA approval before marketing. Most donor-derived perinatal products fall into this category.
The practical effect: an autologous bone-marrow procedure performed in a single visit, with no expansion and no donor cells, can operate as a clinical procedure. A donor-derived umbilical-cord or placental product injected for the same indication usually requires full FDA approval, which most marketed products do not have.
Plain-language summary
In short: your own cells, used the same day with minimal processing, are usually treated as a clinical procedure. Donor cells, especially from umbilical cord, placenta, or amniotic tissue, are usually treated as a drug that needs FDA approval.
03 · Where enforcement is focused
Why FDA enforcement has focused on donor-derived products.
Regulatory framing, Boulder Biologics
"The FDA has raised particular concern regarding allogeneic (donor-derived) stem cell products, including umbilical cord, placental, and amniotic products, marketed outside of approved clinical trials. This distinction is important, as FDA enforcement actions have primarily targeted unapproved donor-derived products marketed without appropriate authorization."
The pattern of FDA enforcement actions since the agency began ramping up oversight in 2017 has been consistent. Many FDA warning letters have gone to clinics and manufacturers selling donor-derived products. The two major court cases went differently: US Stem Cell (2019) and California Stem Cell Treatment Center (2024) both involved clinics that processed patients' own fat into cell products (stromal vascular fraction).3,7
The FDA has given these reasons:
- Patient harm from contamination. Donor products manufactured at scale, especially with inadequate sterility controls, have caused bacterial sepsis, including bloodstream infections requiring hospitalization. In 2018, the CDC reported 12 patients in three states who were hospitalized with infections, including bloodstream infections, after injections of contaminated umbilical cord blood products from one distributor.4
- Patient harm from unproven claims. Donor-product clinics frequently market for indications (ALS, autism, MS, severe arthritis, COPD, diabetes) where no evidence supports the claimed benefit and where patients may forgo evidence-based care.
- Lack of identity, potency, or sterility documentation. Donor products vary widely from batch to batch, with poor quality control. Many products marketed as containing "millions of live stem cells" have been shown on testing to contain few or no live cells.
- Marketing language that misleads patients. "FDA registered," "regenerative," "cure," "reverse aging", all language the agency has cited as misleading in enforcement letters.
04 · The marketing reality
Why patients encounter donor products anyway.
Despite the regulatory exposure and the FDA enforcement record, donor-derived "stem cell" products remain widely marketed in the U.S. Several reasons:
- Convenience for clinics. Donor products ship from manufacturers ready-to-inject. No harvesting equipment, no on-site lab, no aspiration procedure. A clinic can offer "stem cell therapy" with minimal capital investment and no specialized procedural training.
- The word "stem cell" sells. Patients searching for help with chronic conditions find clinics offering "stem cells" and reasonably assume that every "stem cell" treatment is the same, clinically and legally. It is not.
- Slow compliance. In 2019, the FDA said that "countless clinics" were still marketing stem cell products that violate its rules, and that the industry had made only "modest progress" toward compliance.2
- Implicit FDA-approval framing. Clinics often describe themselves as "FDA registered" (registration means the facility is listed with the FDA; the FDA does not review whether its products are safe or work) or list their facility registration as if it were an approval. Patients reasonably read this as endorsement.
05 · How to evaluate a clinic
What to look for, and what to look out for.
Good signals:
- The clinic tells you the product or procedure is not FDA-approved, rather than implying it is.
- Cells used are autologous, your own, and the harvesting procedure is performed in the same visit.
- The clinic does not use donor-derived umbilical cord, placental, or amniotic products.
- A physician performs the bone marrow harvest personally.
- There is a clear regulatory-disclosure page that explains the HCT/P framework and the clinic's position within it.
- Outcome language is conservative ("may help," "supports," "evidence is preliminary") and avoids words like "cures," "reverses," and "regenerates."
- Informed-consent documentation discusses the investigational nature of the approach where applicable.
Red flags:
- "FDA approved" without naming a specific approved product and indication.
- "FDA registered" presented as if it means "approved."
- Donor-derived products (cord, placental, amniotic) advertised for orthopedic, neurological, autoimmune, or wellness indications.
- Cure language or specific outcome guarantees.
- Heavy use of before-and-after marketing.
- Claims of "millions of live stem cells" without supporting documentation of cell count and viability.
- Generalist marketing for everything, joints, brain, lungs, autoimmune, anti-aging.
06 · Where we stand
The Boulder Biologics position.
Boulder Biologics
"At Boulder Biologics, we use autologous stem cells only."
This is a clinical and regulatory position. In practice, it means:
- No donor cells. No umbilical cord blood. No umbilical cord tissue. No placental products. No amniotic membrane. No amniotic fluid. No commercially-purchased cell products of any kind.
- No culture expansion. Your bone marrow aspirate is processed on-site within the same procedural window, returned to your own body the same day, and the cellular composition is what your marrow naturally contains, not what a lab grew.
- No genetic modification. No engineered cells (such as the CAR-T cells used in some cancer care) and no off-the-shelf cell lines.
- Patient-derived only. Everything we use comes from your own body on the day of your procedure: bone marrow, platelet-rich plasma, and, for structural cushioning only, microfragmented fat tissue.
The autologous-only position is also the position that allows us to operate within the same-surgical-procedure exception of 21 CFR 1271.15(b), as a clinical procedure performed within the framework the FDA's HCT/P regulations establish.
07 · Common questions
Frequently asked.
Are donor-derived stem cells ever appropriate? +
Yes, in the right context. Hematopoietic stem cell transplants (HSCT) for blood cancers and certain inherited disorders are donor-derived (or in some cases autologous) and have full FDA approval. These are not the same as the donor-derived "stem cell injection" marketed for joint pain, autism, or anti-aging.
The key distinction is: an FDA-approved allogeneic product, used for an approved indication, in an approved setting, is appropriate. A commercially-sold allogeneic product, used off-label, by a clinic with no IND filing, is not.
If donor-derived products were better, wouldn't more clinics use them? +
The popularity of donor-derived products in the U.S. "stem cell clinic" market is driven by convenience and economics, not by clinical superiority. Donor products are easy to stock and inject; autologous procedures require on-site lab capacity, bone-marrow aspiration training, and same-day processing infrastructure. The economics favor donor products for clinics that aren't equipped for autologous work, even though the regulatory and clinical position is harder to defend.
What about MSC immunogenicity, aren't allogeneic MSCs "immune-privileged"? +
That was the original framing, but the literature has moved. Recent work shows that allogeneic MSCs can provoke a measurable immune response in the host, particularly after repeat dosing or once they begin to differentiate (which increases MHC class I and II, the surface markers the immune system uses to spot foreign cells).5,6 The "immune-privileged" claim is now widely considered outdated.
For a deeper read, see our science explainer on mesenchymal stromal cells, specifically the section on allogeneic immunogenicity.
How do I know if a clinic is using autologous or donor cells? +
Ask directly: "Are you using my own cells, harvested today, or are you using a product that arrives in a vial from a supplier?" A clinic using autologous material will be able to describe the harvesting procedure (typically iliac crest bone marrow aspiration); a clinic using donor products often defers to the manufacturer for source details. If the answer involves anything labeled "umbilical cord," "Wharton's jelly," "placental," "amniotic," or a brand name like StemFx, Liveyon, RegenMD, etc.: those are donor products.
References
Sources cited.
- 21 CFR Part 1271, Human Cells, Tissues, and Cellular and Tissue-Based Products. Electronic Code of Federal Regulations.
- U.S. Food and Drug Administration. Statement by FDA Commissioner Scott Gottlieb, M.D., and Biologics Center Director Peter Marks, M.D., Ph.D. on FDA's continued efforts to stop stem cell clinics and manufacturers from marketing unapproved products that put patients at risk. April 3, 2019.
- U.S. Food and Drug Administration. Statement on stem cell clinic permanent injunction and FDA's ongoing efforts to protect patients from risks of unapproved products. June 25, 2019.
- Perkins KM, Spoto S, Rankin DA, et al. Notes from the Field: Infections after receipt of bacterially contaminated umbilical cord blood–derived stem cell products for other than hematopoietic or immunologic reconstitution, United States, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(50):1397–1399.
- Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252–60.
- Joswig AJ, Mitchell A, Cummings KJ, et al. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model. Stem Cell Res Ther. 2017;8(1):42.
- United States v. California Stem Cell Treatment Center, Inc., No. 22-56014 (9th Cir. Sept. 27, 2024).
Related patient explainers